Teligent Revenue 2012-2021 | TLGT
Teligent revenue from 2012 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
|
Teligent Annual Revenue (Millions of US $) |
|
|---|---|
| 2020 | $45 |
| 2019 | $66 |
| 2018 | $66 |
| 2017 | $60 |
| 2016 | $63 |
| 2015 | $44 |
| 2014 | $34 |
| 2013 | $18 |
| 2012 | $9 |
| 2011 | $8 |
|
Teligent Quarterly Revenue (Millions of US $) |
|
|---|---|
| 2021-06-30 | $10 |
| 2021-03-31 | $12 |
| 2020-12-31 | $10 |
| 2020-09-30 | $14 |
| 2020-06-30 | $14 |
| 2020-03-31 | $7 |
| 2019-12-31 | $16 |
| 2019-09-30 | $18 |
| 2019-06-30 | $18 |
| 2019-03-31 | $13 |
| 2018-12-31 | $17 |
| 2018-09-30 | $18 |
| 2018-06-30 | $16 |
| 2018-03-31 | $15 |
| 2017-12-31 | $11 |
| 2017-09-30 | $11 |
| 2017-06-30 | $18 |
| 2017-03-31 | $20 |
| 2016-12-31 | $14 |
| 2016-09-30 | $16 |
| 2016-06-30 | $17 |
| 2016-03-31 | $16 |
| 2015-12-31 | $13 |
| 2015-09-30 | $12 |
| 2015-06-30 | $9 |
| 2015-03-31 | $11 |
| 2014-12-31 | $14 |
| 2014-09-30 | $7 |
| 2014-06-30 | $6 |
| 2014-03-31 | $7 |
| 2013-12-31 | $7 |
| 2013-09-30 | $4 |
| 2013-06-30 | $4 |
| 2013-03-31 | $4 |
| 2012-12-31 | $2 |
| 2012-09-30 | $2 |
| 2012-06-30 | $2 |
| 2012-03-31 | $2 |
| 2011-12-31 | $2 |
| 2011-09-30 | $2 |
| 2011-06-30 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.000B | $0.000B |
| Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |